Search

Displaying results 3621 - 3630 of 4359 in total
  1. Drug

    Butenafine

    go.drugbank.com/drugs/DB01091
    Approved

    Butenafine hydrochloride is a synthetic benzylamine antifungal agent. Butenafine's mechanism of action is believed to involve the synthesis inhibition of sterols. In particular, butenafine acts to inhibit the activity of the squalene epo...

  2. Drug

    Carbenicillin

    go.drugbank.com/drugs/DB00578
    Approved

    Broad-spectrum semisynthetic penicillin derivative used parenterally. It is susceptible to gastric juice and penicillinase and may damage platelet function.

  3. Drug

    Astemizole

    go.drugbank.com/drugs/DB00637
    ApprovedWithdrawn

    Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especi...

  4. Drug

    Spirapril

    go.drugbank.com/drugs/DB01348
    ApprovedInvestigational

    Spirapril is an ACE inhibitor antihypertensive drug used to treat hypertension. Spirapril is converted to the active spiraprilat after administration. ACE inhibitors are used primarily in treatment of hypertension and congestive heart fa...

  5. Drug

    Suvorexant

    go.drugbank.com/drugs/DB09034
    ApprovedInvestigational

    Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.

  6. Drug

    Deutarserine

    go.drugbank.com/drugs/DB19057
    Investigational

    Deutarserine is under investigation in clinical trial NCT04158687 (A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia).

  7. Drug

    Leuvectin

    go.drugbank.com/drugs/DB17303
    Investigational

    Leuvectin (formerly known as VCL-1102) is a component of gene therapy along with cationic lipid 1,2-dimyristyloxypropyl-3-dimethyl-hydroxyethyl ammonium bromide/dioleyl-phosphatidyl-ethanolamine (DMRIE

  8. Drug

    PF-06291874

    go.drugbank.com/drugs/DB15065
    Investigational

    PF-06291874 is under investigation in clinical trial NCT02175121 (Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study of PF-06291874 as Oral Monotherapy To Treat Adults With Type 2 Diabetes

  9. Drug

    2'-Fucosyllactose

    go.drugbank.com/drugs/DB16052
    Investigational

    2'-Fucosyllactose is under investigation in clinical trial NCT03847467 (Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-tnf Therapy).

  10. Drug

    Afelimomab

    go.drugbank.com/drugs/DB04956
    Experimental

    Afelimomab (also known as Fab 2 or MAK 195F) is an anti-TNF-α monoclonal antibody. Administration of 195F reduces the concentration of interleukin-6 in patients with sepsis.